RxDoctor Payments Data

John Ball, PA

Physician Assistant · Salt Lake City, UTNPI 1003975145

Payments from drug & device makers

$546in general payments, 2019–2025

Across 33 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$233
  • Dexcom, Inc.$90
  • BETA Bionics, Inc.$85
  • Tandem Diabetes Care, Inc.$43
  • Lilly USA, LLC$31
  • AstraZeneca$30
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$546 in reported general payments places this provider in the 60th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$32,381
Medicare patients
89
Services billed
536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide398$477,864
JardianceEmpagliflozin220$187,993
FarxigaDapagliflozin Propanediol165$131,689
OzempicSemaglutide115$125,651
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog79$112,910
TrulicityDulaglutide79$93,747
Tresiba Flextouch U-200Insulin Degludec26$39,216
Soliqua 100-33Insulin Glargine/Lixisenatide35$34,222
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog40$21,763
Xigduo XrDapaglifloz Propaned/Metformin17$13,842
Xultophy 100-3.6Insulin Degludec/Liraglutide11$13,725
Humalog Kwikpen U-100Insulin Lispro56$11,474
Lantus SolostarInsulin Glargine,hum.Rec.Anlog76$11,458
TradjentaLinagliptin12$6,049
Fiasp FlextouchInsulin Aspart (Niacinamide)11$5,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$31$571,611477 claims
Novo NordiskOzempic, Xultophy 100-3.6$17$139,376126 claims
AstraZenecaFarxiga$30$131,689165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →